Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15894977 | 0.94 | APP (0.31) | SMN1; SMN2KMT2APSMB8 | |
| SCHEMBL3834792 | 0.87 | PARL (0.33) | PSMB8 | |
| SCHEMBL379163 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTPSMB8 | |
| SCHEMBL4960230 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTPSMB8 | |
| SCHEMBL1870550 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTPSMB8 | |
| SCHEMBL905404 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTPSMB8 | |
| SCHEMBL905722 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTPSMB8 | |
| SCHEMBL905700 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTPSMB8 | |
| SCHEMBL37833 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTPSMB8 | |
| SCHEMBL16983769 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTPSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9480751-B2 | Albumin binding probes and drug conjugates thereof | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-11-01 | — | — | US | disclosed |
| US-20150202310-A1 | ALBUMIN BINDING PROBES AND DRUG CONJUGATES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2015-07-23 | — | — | US | disclosed |
| EP-2696897-A2 | ALBUMIN BINDING PROBES AND DRUG CONJUGATES THEREOF | Yeda Research and Development Co. Ltd. (IL) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012140647-A2 | ALBUMIN BINDING PROBES AND DRUG CONJUGATES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202310-A1 | ALBUMIN BINDING PROBES AND DRUG CONJUGATES THEREOF | FABP1, FABP5, ALB | SMN1; SMN2 4109/4885KMT2A 2435/4885HPGD 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.